Styrelse

This section provides the financial market, owners and other interested parties with correct, relevant and timely information about our business and our performance. Investor information is released in Swedish for regulatory reasons and translated into English on a report-to-report basis. Please contact Redsense for additional information.

Bo Unéus

Bo Unéus

Chair of the Board

Elected Chairman: 2017 (elected as Board Member 2014)

Previous positions: Has held senior positions at Nordstjernan and Skåne-Gripen and worked for many years on an international level. Worked with change processes for larger companies and groups, including Fiat in Turin. Sales manager at BTS, Celemi, Skåne-Gripen AB.

Shareholding: 26,500 shares and 72,463 stock options

Bo Unéus is independent of the Company and its management.

Susanne Olausson

Susanne Olausson

Member of the Board

Elected: 2013

Previous positions: Has twenty years of sales experience in the pharmaceutical industry, the medical technology industry and life science. Has held positions as VP Commercial Operations, European Congress Manager, Director Sales & Marketing development, product specialist and product manager in medical technology and pharma.

Shareholding: 72,463 stock options

Klas Arildsson

Klas Arildsson

Member of the Board

Elected: 2017

Previous positions: Has held several leading positions within Ericsson Telecom, such as Quality Manager and Plant Manager. VP of Operations at Cardo Door and member of the management team of the business area. Senior VP of Global Supply Chain at Gambro Renal Products, and Vice President of the business area. VP Supply Chain Manufacturing Baxter Inc. and Vice President of the business area. VP Operations Getinge Infection AB. Other directing positions and assignments: Several international assignments for Cardo Door, Gambro Lundia AB and Getinge Infection AB. Board member of Gambro Lundia AB and part of Lund University’s Business Council. Former corporate involvement: Director of Lund Nyföretagarcentrum and Life Assays AB. Currently chairman of the board of listed company Dignitana and the Kristianstad Österlen Airport.

Shareholding: 15,000 shares and 72,463 stock options

Klas Arildsson is independent of the Company and its management.

Jörgen Hegbrant

Jörgen Hegbrant

Member of the Board

Elected: 2017

Previous positions: Has 35+ years of working experience in the field of nephrology and internal medicine, with 25 years of experience in senior positions in global companies in the dialysis business. Served as Senior Vice President & Chief Medical Officer (2007 – August 2019) at Diaverum AB, a global renal service provider operating dialysis clinic in 20+ countries. Prior to Diaverum, he has held leading positions in Gambro as Chief Medical Officer at Gambro Healthcare International and Senior Medical Director at Corporate Research, Gambro AB.  Has solid global knowledge in the area of chronic kidney disease and dialysis, with broad experience from academia, research & development, dialysis clinic operations and healthcare management.

Shareholding: 8,186 shares and 72,463 stock options.

Jörgen Hegbrant is independent of the Company and its management.

Maria Alquist

Maria Alquist

Member of the Board

Elected: 2019

Previous positions: Has held leading positions as VP Global Medical & Scientific, Senior Medical Director Research and Medical Safety at Gambro. Has extensive experience within global kidney care and dialysis companies. Serves as an expert in assessment committees within the Medtech area of the Foundation for Strategic Research, which annually awards around SEK 600 million to strategic research in the natural sciences, technology and medicine.

Shareholding: 2,000 shares and 72,463 stock options

Maria Alquist is independent of the Company and its management.

Annette Colin

Annette Colin

Member of the Board

Elected: 2021

Previous positions: Annette Colin has more than 25 years of experience in executive positions such as CEO, CFO, COO, Group Financial Controller and Tax Manager, including 15 years in Life Science.  Annette has been part of fast-growing companies and organizations and has broad finance skills and long experience in, among other things, building strategic planning, raising capital, business development, leadership development, streamlining infrastructure and Investor Relations. She has been involved in several M&A and IPO transactions and worked with both Venture Capital, Private Equity owners and the majority in Publicly listed companies, from start-ups to Large Cap companies.

Most recent assignments include Annexin Pharmaceuticals AB (publ) Observe Medical International (publ), Stille AB (publ), Lindab International AB (publ), Perbio Science AB (publ) and EY. She is currently board member of Initiator Pharma A/S and Sozap AB (publ). Today Annette is Group CFO and responsible for IR at Biotage AB (publ). She has education in Business Administration and law at Lund University, Sweden.

Shareholding: 0

Annette Colin is independent of the Company and its management.